Hetero has launched its generic semaglutide portfolio in overseas markets even as it is awaiting regulatory approvals in India. The launch represents the beginning of a strategic, multi-year global ...

Semaglutide is part of a group of medicines called GLP-1 receptor agonists, commonly used to manage type 2 diabetes. In recent years, it has also gained worldwide attention for helping with weight ...

The FDA has approved a generic version of fluticasone propionate (marketed as Flovent HFA), according to a statement issued on March 3. The approval extends the accessibility of the medication, ...

Generic versions of Novo Nordisk A/S’s hit shots Ozempic and Wegovy could be sold for under $3 a month, a new study showed, underscoring their potential to unlock global access to powerful weight-loss ...

BuyCanadianInsulin.com reports that generic semaglutide may become available in Canada in 2026 following changes in regulatory protections associated with the medication. The development reflects a ...

Feb 25 - Zydus Lifesciences (ZYDU.NS), opens new tab will launch generic versions of semaglutide injections for obesity and diabetes in India after patent expiry of the Ozempic active ingredient in ...

The following is a news release from the Idaho Attorney General's Office: BOISE, Idaho — On February 2, 2026, Attorney General Labrador joined a coalition of 48 states and territories announcing ...

Oklahomans who purchased certain generic prescription drugs between 2009 and 2019 may be eligible for compensation after two pharmaceutical companies agreed to pay $17.85 million to settle allegations ...

New Jersey has joined 42 other states in suing global pharmaceutical company Novartis and its spin-off Sandoz for engaging in what they describe as “one of the most egregious examples of ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. ProPublica on Friday published never-before-released data ...

Dr. Reddy's Laboratories (RDY) on Wednesday announced that India’s drug regulator, the Drugs Controller General of India, has issued marketing and manufacturing authorization for a generic version of ...

“Congress… evidently viewed that prospect [of off-label, patented uses] as an acceptable cost of expedited competition with respect to lawful unpatented uses.” – U.S. Solicitor General On Friday, the ...